These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 15141738)

  • 1. Impact of tuberculosis on the course of HIV-infected patients with a high initial CD4 lymphocyte count.
    Mañas E; Pulido F; Peña JM; Rubio R; Gonzalez-García J; Costa R; Pérez-Rodríguez E; Del Palacio A
    Int J Tuberc Lung Dis; 2004 Apr; 8(4):451-7. PubMed ID: 15141738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
    AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Natural history of human immunodeficiency virus infection in a cohort of Chilean patients].
    Vial PA; Ferreccio C; Abarca K; Ortiz E; Noriega M; Pérez C; Labarca J; Torres M; Ferrés M; González C; Acuña G
    Rev Med Chil; 1996 May; 124(5):525-35. PubMed ID: 9035503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area.
    Badri M; Ehrlich R; Wood R; Pulerwitz T; Maartens G
    Int J Tuberc Lung Dis; 2001 Mar; 5(3):225-32. PubMed ID: 11326821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients.
    Goujard C; Bonarek M; Meyer L; Bonnet F; Chaix ML; Deveau C; Sinet M; Galimand J; Delfraissy JF; Venet A; Rouzioux C; Morlat P;
    Clin Infect Dis; 2006 Mar; 42(5):709-15. PubMed ID: 16447119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secular trends in the survival of HIV-infected homosexual men in Amsterdam and Vancouver estimated from a death-included CD4-staged Markov model.
    Hendriks JC; Craib KJ; Veugelers PJ; van Druten HA; Coutinho RA; Schechter MT; van Griensven GJ
    Int J Epidemiol; 2000 Jun; 29(3):565-72. PubMed ID: 10869332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of drug-resistant tuberculosis on the survival of HIV-infected patients.
    Sungkanuparph S; Eampokalap B; Chottanapund S; Thongyen S; Manosuthi W
    Int J Tuberc Lung Dis; 2007 Mar; 11(3):325-30. PubMed ID: 17352100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of tuberculosis in HIV-infected patients receiving HAART: interaction between TST and CD4 count.
    Martín-Echevarria E; Rodríguez-Zapata M; Torralba M; Fernández JM; Moreno A; Casado JL; Dronda F; Pérez-Elías MJ; Navas E; Moreno S
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1347-52. PubMed ID: 22283893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
    Wong KH; Chan KC; Lee SS
    Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD4 surveillance in Scotland: perspectives on severe HIV-related immunodeficiency. CD4 Collaborative Group.
    AIDS; 1997 Oct; 11(12):1509-17. PubMed ID: 9342074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
    Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
    J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gender-specific differences in the natural history, clinical features, and socioeconomic status of HIV-infected patients: experience of a treatment centre in Vienna.
    Armbruster C; Kriwanek S; Vorbach H
    Wien Klin Wochenschr; 2000 Sep; 112(17):754-60. PubMed ID: 11042904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does tuberculosis increase HIV load?
    Day JH; Grant AD; Fielding KL; Morris L; Moloi V; Charalambous S; Puren AJ; Chaisson RE; De Cock KM; Hayes RJ; Churchyard GJ
    J Infect Dis; 2004 Nov; 190(9):1677-84. PubMed ID: 15478075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should absolute lymphocyte count be used as a surrogate marker for CD4+ count in patients with HIV/AIDS?
    Jibrin YB; Yusuph H; Garbati MA; Gashau W; Abja UM
    Afr J Med Med Sci; 2006 Mar; 35(1):9-13. PubMed ID: 17209321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year follow-up study.
    Lohse N; Kronborg G; Gerstoft J; Larsen CS; Pedersen G; Pedersen C; Sørensen HT; Obel N
    Clin Infect Dis; 2006 Jan; 42(1):136-44. PubMed ID: 16323104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low CD4+ T-cell count and high HIV viral load precede the development of tuberculosis disease in a cohort of HIV-positive ethiopians.
    Wolday D; Hailu B; Girma M; Hailu E; Sanders E; Fontanet AL
    Int J Tuberc Lung Dis; 2003 Feb; 7(2):110-6. PubMed ID: 12588010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low CD4+ T-cell count and high HIV viral load precede the development of tuberculosis disease in a cohort of HIV-positive Ethiopians.
    Wolday D; Hailu B; Girma M; Hailu E; Sanders E; Fontanet AL
    Ethiop Med J; 2003 Jun; 41 Suppl 1():67-73. PubMed ID: 15227883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-reactive protein is a marker for human immunodeficiency virus disease progression.
    Lau B; Sharrett AR; Kingsley LA; Post W; Palella FJ; Visscher B; Gange SJ
    Arch Intern Med; 2006 Jan; 166(1):64-70. PubMed ID: 16401812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of mucocutaneous manifestations of HIV/AIDS infection with CD4 counts and disease progression.
    Nnoruka EN; Chukwuka JC; Anisuiba B
    Int J Dermatol; 2007 Oct; 46 Suppl 2():14-8. PubMed ID: 17958624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.